Phase 2
Lung Transplant
Intervention Type:
Oral Drug
Funder Type:
Organization | University

Drug Details

Letermovir (PREVYMIS) is a prescription medicine previously approved by the FDA to help to prevent cytomegalovirus (CMV) infection and disease in adults who have received an allogeneic hematopoietic stem cell (bone marrow) transplant and is now being studied in lung transplant recipients (LTRs).

Study Purpose

This is an interventional, open-label, single center, pilot study with historical controls to test the efficacy of letermovir (LET) for the prevention of CMV infection and disease in adult lung transplant recipients (LTRs) with idiopathic pulmonary fibrosis (IPF).

Find a Clinical Trial